Literature DB >> 23328584

Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth.

Devikala Gurusamy1, Jerilyn K Gray, Peterson Pathrose, Rishikesh M Kulkarni, Fred D Finkleman, Susan E Waltz.   

Abstract

Ron receptor kinase (MST1R) is important in promoting epithelial tumorigenesis, but the potential contributions of its specific expression in stromal cells have not been examined. Herein, we show that the Ron receptor is expressed in mouse and human stromal cells of the prostate tumor microenvironment. To test the significance of stromal Ron expression, prostate cancer cells were orthotopically implanted into the prostates of either wild-type or Ron tyrosine kinase deficient (TK(-/-); Mst1r(-/-)) hosts. In TK(-/-) hosts, prostate cancer cell growth was significantly reduced as compared with tumor growth in TK(+/+) hosts. Prostate tumors in TK(-/-) hosts exhibited an increase in tumor cell apoptosis, macrophage infiltration and altered cytokine expression. Reciprocal bone marrow transplantation studies and myeloid cell-specific ablation of Ron showed that loss of Ron in myeloid cells is sufficient to inhibit prostate cancer cell growth. Interestingly, depletion of CD8(+) T cells, but not CD4(+) T cells, was able to restore prostate tumor growth in hosts devoid of myeloid-specific Ron expression. These studies show a critical role for the Ron receptor in the tumor microenvironment, whereby Ron loss in tumor-associated macrophages inhibits prostate cancer cell growth, at least in part, by derepressing the activity of CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328584      PMCID: PMC3602275          DOI: 10.1158/0008-5472.CAN-12-2474

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  STAT3 in immune responses and inflammatory bowel diseases.

Authors:  Xin Yuan Fu
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

2.  Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation.

Authors:  Glendon M Zinser; Mike A Leonis; Kenya Toney; Peterson Pathrose; Megan Thobe; Sarah A Kader; Belinda E Peace; Shirelyn R Beauman; Margaret H Collins; Susan E Waltz
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

3.  Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer.

Authors:  Bryan E Welm; Gerrit J P Dijkgraaf; Anita S Bledau; Alana L Welm; Zena Werb
Journal:  Cell Stem Cell       Date:  2008-01-10       Impact factor: 24.633

4.  Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

Authors:  Jennifer M O'Toole; Karen E Rabenau; Kerri Burns; Dan Lu; Venkat Mangalampalli; Paul Balderes; Nicole Covino; Rajiv Bassi; Marie Prewett; Kimberly J Gottfredsen; Megan N Thobe; Yuan Cheng; Yiwen Li; Daniel J Hicklin; Zhenping Zhu; Susan E Waltz; Michael J Hayman; Dale L Ludwig; Daniel S Pereira
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

5.  Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.

Authors:  Ami S Bhatt; Alana Welm; Christopher J Farady; Maximiliano Vásquez; Keith Wilson; Charles S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

Review 6.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 7.  Ron-receptor tyrosine kinase in tumorigenesis and metastasis.

Authors:  Mike A Leonis; Megan N Thobe; Susan E Waltz
Journal:  Future Oncol       Date:  2007-08       Impact factor: 3.404

8.  Ron receptor tyrosine kinase-dependent hepatic neutrophil recruitment and survival benefit in a murine model of bacterial peritonitis.

Authors:  Charles C Caldwell; Andre Martignoni; Mike A Leonis; Hari Kumar Ondiveeran; Alison E Fox-Robichaud; Susan E Waltz
Journal:  Crit Care Med       Date:  2008-05       Impact factor: 7.598

9.  The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Authors:  Ryan M Thomas; Kenya Toney; Cecilia Fenoglio-Preiser; Monica P Revelo-Penafiel; Sunil R Hingorani; David A Tuveson; Susan E Waltz; Andrew M Lowy
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-beta gene therapy.

Authors:  M V Olson; J Lee; F Zhang; A Wang; Z Dong
Journal:  Cancer Gene Ther       Date:  2006-02-10       Impact factor: 5.987

View more
  30 in total

Review 1.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

2.  Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in mice.

Authors:  William D Stuart; Nicholas E Brown; Andrew M Paluch; Susan E Waltz
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-02-03       Impact factor: 4.310

3.  SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.

Authors:  Hao Yu; Yudong Liu; Braden C McFarland; Jessy S Deshane; Douglas R Hurst; Selvarangan Ponnazhagan; Etty N Benveniste; Hongwei Qin
Journal:  Cancer Immunol Res       Date:  2015-02-03       Impact factor: 11.151

Review 4.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

Review 5.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

6.  Hepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesis.

Authors:  Devikala Gurusamy; Sasha J Ruiz-Torres; Abby L Johnson; Dana A Smith; Susan E Waltz
Journal:  Mech Dev       Date:  2014-07-15       Impact factor: 1.882

Review 7.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

8.  Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans.

Authors:  Roble G Bedolla; Dimpy P Shah; Shih-Bo Huang; Robert L Reddick; Rita Ghosh; Addanki P Kumar
Journal:  Mol Carcinog       Date:  2019-03-11       Impact factor: 4.784

9.  Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity.

Authors:  Henok Eyob; Huseyin Atakan Ekiz; Yoko S Derose; Susan E Waltz; Matthew A Williams; Alana L Welm
Journal:  Cancer Discov       Date:  2013-04-23       Impact factor: 39.397

10.  Ron receptor signaling is protective against DSS-induced colitis in mice.

Authors:  Rishikesh M Kulkarni; William D Stuart; Devikala Gurusamy; Susan E Waltz
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.